Giacchino M, Vai S, Savant-Levet P, Balbo L, Oderda S, Massara F M, Ferrero Poschetto C, Valori A, Miniero R
Dipartimento di Scienze Pediatriche e dell'Adolescenza, Università degli Studi, Torino.
Minerva Pediatr. 1996 Oct;48(10):445-9.
In this retrospective study we report the incidence of CVC-related infections in a pediatric oncology population during the off therapy period. We analysed 128 children with oncologic diseases (solid tumors and leukemia), 78 boys and 50 girls, aged 1 to 21 years, who maintained the CVC in situ at least 6 months after the cessation of chemotherapeutic protocols. Seventy-eight patients had a single lumen Broviac-Hickman CVC, 8 patients had a double lumen Broviac-Hickman and 42 a implantable port device. The permanence of CVC in situ after discontinuation of treatment varied between 6 and 24 months. CVC was removed in 5 patients that presented a CVC-related infection, respectively 6, 6, 6, 7 and 10 months from discontinuation of therapy, in 85 patients because was considered no more necessary. 38 patients are still with CVC in situ; in this group 11 patients relapsed more than 6 months after discontinuation of the therapy and were analysed until the time of relapsed. The result of our study show that the incidence of CVC related infections in patients off therapy is very low. Considering the discomfort that frequent blood withdrawals cause to children and the relapse risk, we think that CVC may be maintained in situ more than 6 months after discontinuation of the therapy without risks for the patients.
在这项回顾性研究中，我们报告了儿科肿瘤患者在停止治疗期间中心静脉导管（CVC）相关感染的发生率。我们分析了128例患有肿瘤疾病（实体瘤和白血病）的儿童，其中78名男孩和50名女孩，年龄在1至21岁之间，他们在化疗方案停止后至少6个月内保持CVC在位。78例患者使用单腔Broviac-Hickman CVC，8例患者使用双腔Broviac-Hickman CVC，42例患者使用植入式端口装置。治疗停止后CVC在位的时间在6至24个月之间。5例出现CVC相关感染的患者分别在停止治疗后6、6、6、7和10个月拔除了CVC，85例患者因认为不再需要而拔除。38例患者的CVC仍在位；在该组中，11例患者在停止治疗6个月后复发，并在复发时进行了分析。我们的研究结果表明，停止治疗的患者中CVC相关感染的发生率非常低。考虑到频繁采血给儿童带来的不适以及复发风险，我们认为在停止治疗后CVC可以在位保留超过6个月，而对患者没有风险。
